Impressive early results for Vertex’s potentially curative stem cell diabetes therapy
A cure for Type 1 diabetes has come one step closer as Vertex reports 90-day...
Analysis
Joe Biden’s global corporation tax deal: A prediction on what’s next
Why have the nations of the world agreed to a new minimum corporation tax rate?...
Robotics hiring levels in the clinical trial operations industry rose in August 2021
19.7% of the companies included in our analysis recruited for at least one robotics-related position.
Regulatory roundup: Novartis’s breast cancer SERD tumbles after Phase I/Ib termination
Johnson & Johnson’s RVS vaccine and Enanta’s revised plans in NASH are among other assets...
Sagimet embraces AI-driven pathology for more consistent NASH analysis
In NASH trials, classifying patients between different fibrosis stages can be tricky due to pathologist...
Quest persists for ideal Covid-19 booster timelines, vaccine mixing in blood cancers
While the FDA contemplates Covid-19 booster use, researchers have begun investigating their activity in blood cancer patients.
Cloud hiring levels in the clinical trial operations industry rose to a year-high in August 2021
45.1% of the companies included in our analysis recruited for at least one cloud-related position.
AI is coming — and you can take that to the bank
AI can leverage banks' biggest asset: data, which many a startup would die for. This can save waning banks and provide new income sources.
Remote communities of healthcare professionals are enabling DCTs
Hawthorne Effect’s Hero network is enabling continuous data capture in remote and hard to reach communities.
Uneven Covid-19 vaccine efficacy in blood cancers mean masks to stay
A quarter of haematological cancer patients do not mount an effective immune response after Covid-19 vaccination.
Regulatory roundup: Editas’ CRISPR asset make strides after positive eye disease trial
MacroGenics in multiple cancers and Merck’s Bavencio are among other assets reviewed by GlobalData’s Investigative News team.
